# Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

Source: https://onco.cc/trials/nct06807359/  
OnCo record `nct06807359` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Photodynamic Therapy (PDT) in prostate cancer, run by SpectraCure AB, now recruiting.

## Summary

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System is a phase 1/2 interventional study registered as NCT06807359 by SpectraCure AB, with 43 participants planned, started 2025-01-06 and due to reach its primary completion in 2028-01. Interventions recorded: Photodynamic Therapy (PDT) and Verteporfin Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06807359
- Phase: 1/2
- Setting: Open-label Clinical Phase 1/2 Study to Assess the Safety and Efficacy of the SpectraCure P18 System and Verteporfin for Injection for the Treatment of Primary Localized Prostate Cancer
- Sponsor: SpectraCure AB
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT06807359: https://clinicaltrials.gov/study/NCT06807359

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [SpectraCure](https://onco.cc/companies/spectracure/)

---
JSON: https://onco.cc/api/v1/entities/nct06807359.json